Mar 16, 2021 9:00am EDT CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
Mar 12, 2021 9:00am EST CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
Jan 11, 2021 9:00am EST CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS
Dec 09, 2020 9:00am EST CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model
Nov 16, 2020 4:01pm EST CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update